Immunization for Ebola virus infection

Abstract

Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.

1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . The pharmaceutical composition of  claim 8 , wherein the control sequence is a promoter.  
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the promoter is the CMV immediate-early region 1 promoter.  
     
     
         5 . The pharmaceutical composition of  claim 8 , further comprising an adjuvant.  
     
     
         6 . (canceled)  
     
     
         7 . (canceled)  
     
     
         8 . A pharmaceutical composition comprising a nucleic acid molecule encoding an Ebola virus structural gene product operatively-linked to a heterologous control sequence, in a pharmaceutically acceptable carrier, wherein the Ebola virus structural gene product is virus nucleoprotein.  
     
     
         9 . A method of producing a vaccine against disease caused by infection by Ebola virus, comprising the steps of: 
 a) administering the pharmaceutical composition of  claim 8  to a test host to determine an amount and a frequency of administration thereof to elicit a protective immune response in said host; and    b) formulating said pharmaceutical composition in a form suitable for administration to a treatable host in accordance with said determined amount and frequency of administration.    
     
     
         10 . (canceled)  
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . (canceled)  
     
     
         14 . (canceled)  
     
     
         15 . (canceled)  
     
     
         16 . (canceled)  
     
     
         17 . (canceled)  
     
     
         18 . A vaccine comprising a nucleic acid molecule encoding the Ebola virus nucleoprotein operatively-linked to a heterologous control sequence, in a pharmaceutically acceptable carrier.  
     
     
         19 . The vaccine of  claim 18 , wherein the control sequence is a promoter.  
     
     
         20 . The vaccine of  claim 19 , wherein the promoter is the CMV immediate-early region 1 promoter.  
     
     
         21 . The vaccine of  claim 18 , further comprising an adjuvant.  
     
     
         22 . (canceled)  
     
     
         23 . A method of immunizing a subject against hemorrhagic fever comprising the step of administering to the host an immunoeffective amount of the vaccine of any of  claims 18  to  21 , wherein the hemorrhagic fever is caused by infection with Ebola virus.  
     
     
         24 . (canceled)  
     
     
         25 . The method of  claim 23 , wherein the host is a human and administration is by intramuscular injection.  
     
     
         26 . The method of  claim 23 , wherein the subject receives a second administration of an immunoeffective amount of a vaccine against disease caused by infection by Ebola virus.